The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Taxation/Internal Revenue Code

Issues related to coverage of over-the-counter products with FSAs and HSAs.

Budget/Appropriations

Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).

Trade (domestic/foreign)

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

Medicare/Medicaid

Education about the importance of OTC products and benefits under Medicare Advantage.

Health Issues

Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use.

Bills named in this filing 3

H.R. 5166
Financial Services and General Government Appropriations Act, 2026
S. 3290
Financial Services and General Government Appropriations Act, 2026
H.R. 7148
Consolidated Appropriations Act, 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.